On the cover: Top row (left to right): Elizabeth M. Jaffee, MD, FAACR, 2018-2019 AACR President; Chuck Dandridge (second from right), an acute myeloid leukemia survivor featured in the AACR Cancer Progress Report 2018; Michael A. Caligiuri, MD, FAACR, 2017-2018 AACR President; Tori Lee (center), a leukemia survivor featured in the AACR Cancer Progress Report 2018. DRIVING INNOVATIVE Middle row (left to right): Margaret Foti, AACR Chief Executive Officer; Laurie Trotman, a breast cancer survivor featured in the AACR Cancer CANCER SCIENCE Progress Report 2018. TO PATIENT CARE Bottom row (left to right): Lucile L. Adams-Campbell, PhD, Chair of the AACR Women in Cancer Research Council; Mike Delia, a non-Hodgkin lymphoma survivor featured in the AACR Cancer Progress Report 2018; James P. Allison, PhD, FAACR, a former member of the AACR Board of Directors who received the Nobel Prize in Physiology or Medicine in 2018 for his shared discovery of cancer therapy by inhibition of negative immune regulation; Ron Scolamiero (left), a prostate cancer survivor featured in the AACR Cancer Progress Report 2018. AACR.org/AnnualReport18 AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL REPORT 1810051_AACR2018AnnRepCOV_11x8.5_2.indd All Pages 6/3/19 12:04 PM AACR.org • Follow us: blog.aacr.orgDONATE WELCOME: DRIVING INNOVATIVE CONTENTS CANCER SCIENCE TO PATIENT CARE 2 PROGRESS AGAINST CANCER IN 2018 4 AACR ANNUAL MEETING 2018 8 SCIENTIFIC PUBLISHING 16 2 4 8 AACR INTERNATIONAL 22 HONORING SCIENTIFIC ACHIEVEMENT 26 SCIENCE AND EDUCATION 34 SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION 46 16 22 26 34 POLICY AND ADVOCACY 54 54 62 68 MEMBERSHIP 62 LEADERSHIP 68 46 AACR FOUNDATION 78 FINANCIAL STATEMENT 90 78 90 92 THE AACR IN 2019: A LOOK AHEAD 92 American Association for Cancer Research Annual Report 2018 I 1 1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 2-1 6/3/19 11:30 AM WELCOME DRIVING INNOVATIVE CANCER SCIENCE TO PATIENT CARE Dear Colleagues The theme of the AACR Annual Meeting of cancer treatment—and celebrated a Conference is an example of the AACR’s 2018, “Driving Innovative Cancer Science major accomplishment by one of our most global collaboration to advance cancer and Friends: to Patient Care,” is also the theme of this distinguished members. AACR member science. AACR conferences such as this one report. The report outlines all the ways and Fellow of the AACR Academy James bring together the greatest minds in cancer in which AACR programs and initiatives P. Allison, PhD, FAACR—along with his research to share the latest developments We are pleased to present support the efforts of investigators from the colleague, Tasuku Honjo, MD, PhD—was in the field, and special conferences—such the 2018 Annual Report of laboratory to the clinic to improve the lives awarded the Nobel Prize in Physiology as the AACR’s first conference on Tumor of cancer patients. or Medicine in October for his shared Immunology in 2006—identify promising the American Association discovery of cancer therapy by inhibition areas of inquiry and inspire scientists As the report documents, 2018 was a of negative immune regulation. The day to pursue new approaches. And AACR for Cancer Research (AACR). spectacular year for the AACR, one that after the announcement, we were fortunate grants and scientific achievement awards The report highlights the was marked by several milestones. The to have Dr. Allison attend the Fourth CRI- identify promising young investigators and AACR Annual Meeting attracted a record CIMT-EATI-AACR International Cancer accomplished senior scientists—including AACR’s progress over the number of participants, as we welcomed Immunotherapy Conference: Translating Dr. Allison in 2013, 2014, and 2015 (see past year in support of our more than 22,500 scientists, clinicians, Science into Survival. As he entered the p. 30)—and support their efforts to find the other health care professionals, survivors, ballroom for the morning session at the next breakthrough. mission: to prevent and cure and advocates to Chicago to share the conference, Dr. Allison received a standing latest breakthroughs in cancer science. The ovation from his friends, his colleagues, and Continued progress against cancer requires cancer through research, organization expanded its global outreach, the other senior investigators and early- continued inspiration and innovation. As education, communication, collaborating with 16 different international career scientists in attendance. outlined in this report, the AACR meets scientific organizations to foster progress the challenge of driving innovative cancer collaboration, funding, and against cancer around the world. And It is fitting that Dr. Allison was at an AACR science to patient care by pursuing an advocacy. AACR Project GENIE (Genomics Evidence conference to celebrate the breakthroughs agenda that is scientifically bold, broad, and Neoplasia Information Exchange) doubled that led to his recognition by the Nobel collaborative. Powered by the dedicated in size, welcoming 11 new participating committee, as the AACR is uniquely efforts of our 42,000 members, and guided institutions that are committed to its goal positioned to support such breakthroughs by the best minds in cancer research, the of delivering the benefits of precision in all areas of cancer research. As a joint AACR will continue translating knowledge medicine to cancer patients. effort with the Cancer Research Institute into breakthroughs until our mission—the (CRI), the Association for Cancer prevention and cure of all cancers—is In addition to these achievements, in 2018 Immunotherapy (CIMT), and the European realized. we witnessed the confirmation of the place Academy of Tumor Immunology (EATI), of cancer immunotherapy among the pillars the International Cancer Immunotherapy MARGARET FOTI, PHD, MD (HC) ELIZABETH M. JAFFEE, MD, FAACR MICHAEL A. CALIGIURI, MD, FAACR AACR Chief Executive Officer AACR President 2018-2019 AACR President 2017-2018 2 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 3 1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 2-3 6/3/19 11:30 AM PROGRESS AGAINST CANCER 2018 PROGRESS DRIVEN BY RESEARCH AGAINST Research discoveries providing deep insights into the complexities of cancer CANCER 90 are driving vital progress in public 80 health and spurring the development IN 2018 70 of lifesaving improvements across the cancer care spectrum. Research-fueled 60 advances in 2018 include the 18 new 50 therapeutics approved by the U.S. Food 40 and Drug Administration (FDA) for 30 treating patients with various types of 20 cancer. During this time period, the FDA 10 also approved 10 previously approved NUMBER OF NEW ANTICANCER THERAPEUTICS APPROVED BY THE FDA BY THERAPEUTICS APPROVED 0 anticancer therapeutics for treating new 1999-2008 2009-2018 types of cancer. The pace at which research discoveries are being converted to new anticancer therapeutics has been accelerating in recent years, as illustrated by the fact that the number of new anticancer therapeutics approved by the Food and Drug Administration (FDA) from 2009 to 2018 (yellow bar) was more than double the number approved by the agency in the previous decade (1999- 2008; blue bar). Adapted from the AACR Cancer Progress Report 2018 (Fig. 9). A featured survivor in the AACR Cancer Progress Report 2018, Ron Scolamiero (with his wife, Laurie) participated in a clinical trial of apalutamide, a new molecularly targeted therapeutic, to treat his prostate cancer. He is currently cancer free. Apalutamide was approved for patients with non-metastatic castration-resistant prostate cancer in 2018. 4 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 5 1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 4-5 6/3/19 11:30 AM PROGRESS AGAINST CANCER 2018 One of the areas of cancer treatment Another two anticancer therapeutics to in which researchers are making gain FDA approvals in 2018 are providing extraordinarily rapid progress is oncologists with an exciting new way to use immunotherapy, which refers to the use radiotherapy to treat neuroendocrine tumors. of therapeutics that harness the power of These pioneering targeted radiotherapeutics “ Enlisting experts from an NICOLE DICAMILLO CANCER SURVIVOR a patient’s own immune system to treat are benefiting many patients, including Nicole his or her cancer. These revolutionary DiCamillo (far left). even broader spectrum of anticancer therapeutics include seven of the therapeutics to gain FDA approvals in 2018. The AACR is proud to have helped catalyze disciplines, including physics, Including these approvals, the number of the progress made against cancer in 2018 types of cancer that can be treated by at through its many programs, services, and chemistry, engineering, least one immunotherapeutic has more initiatives. For example, early data from A featured survivor in the AACR Cancer Progress Report 2018, Nicole than tripled in the past decade, increasing one of the trials that led to the November mathematics, and computer DiCamillo was diagnosed with gastroenteropancreatic neuroendocrine from just six to 20. 2018 approval of larotrectinib for treating tumor—a rare type of cancer, which used to be called carcinoid cancer, certain patients with solid tumors that have science, will significantly that can arise in the pancreas or in other parts of the gastrointestinal Discoveries that deepen our understanding a particular type of NTRK gene mutation tract—at the age of 27. For the next 12 years she underwent surgeries, of cancer biology are continuing to catalyze were presented at the AACR Annual accelerate the pace of chemoembolizations, radiofrequency ablations, and other treatments, the development of new therapeutics that Meeting 2016. which kept the cancer at bay but did not control the debilitating symptoms target specific molecules involved in cancer progress in the future. and to expand the use of those agents With the number of cancer cases ” it caused. In 2016, Nicole began a targeted radiation treatment called Lutathera, which delivers a radioisotope directly to the cancer cells after it that have already been approved.